Hifibio Therapeutics

Hifibio Therapeutics company information, Employees & Contact Information

HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.
Looking for a particular Hifibio Therapeutics employee's phone or email?

Hifibio Therapeutics Questions

News

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases - Business Wire

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases Business Wire

HiFiBiO Inc - Massachusetts Biotechnology Council

HiFiBiO Inc Massachusetts Biotechnology Council

Hifibio Therapeutics’ BTLA agonist antibody gains US IND clearance - BioWorld MedTech

Hifibio Therapeutics’ BTLA agonist antibody gains US IND clearance BioWorld MedTech

HiFiBiO gets high-five from investors with $75M series D to bring 2 programs into clinic - Fierce Biotech

HiFiBiO gets high-five from investors with $75M series D to bring 2 programs into clinic Fierce Biotech

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023 - Business Wire

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023 Business Wire

CSEM leads the industrialization of HiFiBiO’s complex microfluidic chips - Greater Geneva Bern area

CSEM leads the industrialization of HiFiBiO’s complex microfluidic chips Greater Geneva Bern area

FibroGen nabs rights to HiFiBiO's Galectin-9 programme as part of wider deal - FirstWord Pharma

FibroGen nabs rights to HiFiBiO's Galectin-9 programme as part of wider deal FirstWord Pharma

HiFiBiO raises $37.5M in series B following 2017’s management shuffle - Fierce Biotech

HiFiBiO raises $37.5M in series B following 2017’s management shuffle Fierce Biotech

HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS® Selected Advanced Solid Tumors - Business Wire

HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS® Selected Advanced Solid Tumors Business Wire

After its recent funding round, HiFiBiO pens Takeda R&D collaboration - Fierce Biotech

After its recent funding round, HiFiBiO pens Takeda R&D collaboration Fierce Biotech

Top Hifibio Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant